SUCRALFATE (sucralfate) by Design Pharmaceuticals is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. Approved for the short-term (up to 8 weeks) treatment of active duodenal ulcer. First approved in 2025.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Worked on SUCRALFATE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.